Opinion|Videos|March 28, 2025

Key Considerations for Evaluating Ruxolitinib Cream as a Treatment for Young Children

Lisa Swanson, MD, FAAD, discusses how factors such as the safety profile, efficacy, age-appropriate dosing, and potential long-term effects of ruxolitinib cream would be crucial in determining its place in treatment for young children.

Episodes in this series

This news content has been independently developed and is not endorsed by the American Academy of Dermatology.

Video content above is prompted by the following:

  • When considering an emerging topical JAK inhibitor like ruxolitinib cream for young children, what factors would be most important to you in determining its place in treatment?

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


Latest CME